We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > mantle cell lymphoma

News List

BeiGene's Zanubrutinib to Be Approved in China CPhI.CN
May 26, 2020
Zanubrutinib is one of the world's best-selling BTK inhibitor, with sales in 2019 reached 8.08 billion USD.
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore PharmaSources.com
November 22, 2022
InnoCare Pharma that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL).
BeiGene Receives FDA Breakthrough Therapy Designation for Zanubrutinib americanpharmaceuticalreview
January 16, 2019
BeiGene announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor....